share_log
Hi,
moomoo ID:0
Log Out
English
Back
  • English
  • 中文繁体
  • 中文简体

Protagenic Therapeutics (OTCMKTS:PTIX) Share Price Passes Below 200-Day Moving Average of $0.76

Defense World ·  09/14 14:42

Shares of Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.76 and traded as low as $0.67. Protagenic Therapeutics shares last traded at $0.68, with a volume of 18,049 shares traded.

Protagenic Therapeutics Price Performance

The business's 50 day moving average price is $0.66 and its 200 day moving average price is $0.76. The company has a debt-to-equity ratio of 0.04, a quick ratio of 19.47 and a current ratio of 19.47.

Get Protagenic Therapeutics alerts:

Institutional Trading of Protagenic Therapeutics

An institutional investor recently raised its position in Protagenic Therapeutics stock. Renaissance Technologies LLC raised its stake in shares of Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) by 69.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 102,200 shares of the biotechnology company's stock after acquiring an additional 41,800 shares during the period. Renaissance Technologies LLC owned approximately 0.59% of Protagenic Therapeutics worth $83,000 as of its most recent SEC filing. 3.50% of the stock is currently owned by institutional investors.

Protagenic Therapeutics Company Profile

(Get Rating)

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.

Further Reading

  • Get a free copy of the StockNews.com research report on Protagenic Therapeutics (PTIX)
  • These 3 Reports Will Tell Us Much About the Current Economy
  • Is Five Below Trying to Punch Too High?
  • This Is What To Expect From The S&P 500 Now
  • The Two Things You Need To Know About Oracle's FQ1 Report
  • Three Value Stocks For A Volatile Market

Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.